Inflammatory and Hypercoagulable Biomarkers and Clinical Outcomes in COVID-19 Patients.

ABSTRACT: Systemic inflammation and hypercoagulopathy are known pathophysiological processes of coronavirus disease 2019 (COVID-19), particularly in patients with known cardiovascular disease or its risk factors (CVD). However, whether a cumulative assessment of these biomarkers at admission could contribute to the prediction of in-hospital outcomes remains unknown. The CLAVIS-COVID registry was a Japanese nationwide retrospective multicenter observational study, supported by the Japanese Circulation Society. Consecutive hospitalized patients with pre-existing CVD and COVID-19 were enrolled. Patients were stratified by the tertiles of CRP and D-dimer values at the time of admission. Multivariable Cox proportional hazard models were constructed. In 461 patients (65.5% male; median age, 70.0), the med

SUBMITTER: Kitakata H 

PROVIDER: S-EPMC8304719 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature